Israel signs official deal with Pfizer worth NIS 800million

Israel signed a formal contract with Pfizer Inc. on Friday to receive eight million doses of its coronavirus vaccine candidate, if successful. Pfizer The vaccine will cost the country NIS 800 million, Ynet reported – NIS 100 per dose or NIS 200 per person, because each person needs two doses to be protected. Israel is supposed to provide Pfizer 120 million NIS. cash advance as of this week and an additional 680 million shekels. in January, when vaccines are supposed to start arriving.

“This is a great day for the State of Israel and a great day on the way to our victory over the coronavirus,” Prime Minister Benjamin Netanyahu said on Friday. “Today we see a light at the end of the tunnel. vaccines in Israel. On the contrary, Ynet wrote, the contract includes only an intention to do so “according to the circumstances”. effective. “After reaching a critical milestone in our vaccine development program, the world is starting to hope that a potential vaccine could actually help end this devastating global pandemic,” said Albert Bourla, CEO of Pfizer, during the presentation. signing of the contract with Israel. . “Today, we finalized a critical supply agreement with the Government of Israel that will provide the Israeli people with access to a COVID-19 vaccine once approved by regulatory authorities. Netanyahu added that “Our national mission is to enable immunization of every person in Israel.” … I am working with my colleagues around the world so that we can get the vaccine alongside the major countries of the world. Health Minister Yuli Edelstein also welcomed the signing of the deal, but warned Israelis should not become complacent. “There is no vaccine against complacency,” he said, reminding Israelis to follow health ministry regulations, wear masks and respect social distancing. On Saturday evening, the Department of Health reported that there were 748 people diagnosed with the new virus the day before and 137 between midnight and press time on Saturday. Out of 35,719 people screened, 2.1% of people tested positive. Some 294 people were in serious condition, including 130 who were intubated. The death toll has reached 2,720. Some 500,000 doses of the vaccine are expected to arrive in the country in January – enough to immunize 250,000 people. As such, the mass vaccination will not take place in January and probably not until the middle or the end of 2021, that is to say in about a year. Moreover, even if the Pfizer vaccine is successful and Israel receives its full allocation, only four million of the nearly 10 million Israeli citizens and resident non-citizens will be eligible for protection. According to Ynet, Israel has requested 18.5 million doses of the vaccine, but due to previous commitments to the United States and Europe, Pfizer has said it will provide no more than eight million. And another challenge remains: the Pfizer vaccine must be stored at 70 degrees negative. Celsius and this technology is still not available to transport the vaccine to Israel or secure it on arrival. The company said it is working on this technology and this process. Edelstein said on Friday that Israel was also working on other ways to deal with the virus, such as rapid tests. Israel has concluded vaccine deals with Moderna Inc. and Arcturus, two American companies. Hadassah-University Medical Center signed a memorandum of understanding with Russia for its Sputnik V vaccine, which last week reported 92% efficacy. Israel is also working on its own vaccine against the coronavirus, which was developed by the Israel Institute for Biological Research (IIBR). Hadassah said on Friday it had vaccinated 23 people with Brilife, the name of the IIBR vaccine candidate. “The 23 participants in their 20s to 50s have received the vaccine in the past two weeks and are feeling well,” said Professor Yossi Karko, director of the Clinical Research Center at Hadassah. “They did not suffer from any unusual side effects or medical problems after the vaccine, other than temporary tenderness at the injection site – as expected.” The hospital said patients report their feelings each day through a dedicated app and some have come in for checkups and have not needed any treatment. Ten more people are expected to be vaccinated at Hadassah this week and seven more the following week. A total of 40 people will participate in the phase I trial at the hospital. Some 40 volunteers are participating in the same trial through Sheba Medical Center. The hospital spokesperson did not have an updated number of people vaccinated. “We wish each other success along the way,” Karko said. Israel launched its Phase I trial of the IIBR vaccine on November 1. A phase II study, which will take place in additional medical centers, is expected to begin within the month. In this study, 960 volunteers between the ages of 18 and 85, some with underlying medical conditions, will be vaccinated. Phase II is intended to complete safety testing and determine the correct doses, as well as continue to assess efficacy. If the first two phases are successful, a phase III trial of 30,000 volunteers will begin in April or May for the final phase. Once successfully completed, the vaccine can be approved and the population can be vaccinated against the virus. The IIBR vaccine candidate is based on a well-known vaccination method, the institute said. What is new is the use of a vesicular stomatitis virus (VSV) – a type of virus that does not cause disease in humans. Through genetic engineering, proteins are attached to the VSV virus to form coronavirus “crowns” that are identified by the body as COVID-19. As a result, the body produces antibodies against it. The vaccine has already been tested in pigs and has been shown to be effective.

Source link

About Mildred B.

Check Also

Ex-captain of Puntod barangay, officials ordered dismissal

THE Ombudsman’s Office declared former Puntod village chief Marvin Beja and two other barangay officials …